Attachments:
FileDescriptionFile size
Download this file (HTL PR 8-28-18.pdf)28-August-2018-Press-Release.pdfHamilton Thorne Announces Cdn $10,000,000 Bought Deal Private Placement106 kB

HAMILTON THORNE ANNOUNCES CDN $10,000,000 BOUGHT DEAL PRIVATE PLACEMENT

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION,NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION,DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THEUNITED STATES

BEVERLY, MA and TORONTO, Ontario – August 28, 2018 -Hamilton Thorne Ltd. (TSX-V:HTL), a leading worldwide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it has entered into an agreement with Bloom Burton Securities Inc., on behalf of a syndicate of underwriters that includes Beacon Securities Ltd., and Cormark Securities Inc. (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal private placement basis, 9,090,910 common shares of the Company (the “Common Shares”), at a price of CDN$1.10 per Common Share (the “Offering Price”), for aggregate gross proceeds of CDN$10,000,001 (the “Offering”).

The net proceeds of the Offering will be used for funding cash consideration of future acquisitions and general working capital purposes. 

Closing of the Offering is expected to occur on or about September 20, 2018 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

“This strategic financing positions us to continue to grow Hamilton Thorne through acquisition,” stated David Wolf, President and Chief Executive Officer. “By strengthening our balance sheet and broadening our institutional ownership we will be able to accelerate and expand our acquisition program.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. Such statements include, but are not limited to, the expected closing date of the Offering and the proposed use of proceeds. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable, or to complete the Offering on the proposed terms or at all. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.    
978-921-2050 
ir [AT] hamiltonthorne [DOT] ltd
Michael Bruns, CFO
Hamilton Thorne Ltd.    
978-921-2050 
ir [AT] hamiltonthorne [DOT] ltd
Glen Akselrod
Bristol Investor Relations   
416-737-4467
glen [AT] bristolir [DOT] com

Subscribe to Our Investor Email List